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Abstract 
Background and Aims: Down-regulation of GPx3 accelerated hepatic senescence, which 
further caused overwhelming inflammation and severe liver graft injury. MSCs derived from human 
induced pluripotent stem cells (hiPSC-MSCs) have been developed as more efficient delivery 
vehicle with the property of injury tropism. Here, we aimed to explore the suppressive role of 
GPx3 in hepatic IR injury using novel delivery system of hiPSC-MSCs. 
Methods: The mice IR injury model with partial hepatectomy was established. The engineered 
hiPSC-MSCs delivering GPx3 was constructed. All the mice were segregated into three groups. 
hiPSC-MSC-GPx3, hiPSC-MSC-pCDH (vector control) or PBS were injected via portal vein after 
reperfusion. Liver injury was evaluated by histological and serological test. Hepatic apoptosis was 
detected by Tunel staining and remnant liver regeneration was assessed by Ki67 staining. The role 
of hepatic senescence in liver graft injury was evaluated in rat orthotopic liver transplantation 
model. The suppressive effect of GPx3 on hepatic senescence was examined in mice IR injury 
model and confirmed in vitro. Hepatic senescence was detected by SA-β-Gal and P16/ink4a staining.  
Results: GPx3 can be successfully delivered by hiPSC-MSCs into liver tissues. Histological 
examination showed that hiPSC-MSC-GPx3 treatment significantly ameliorated hepatic IR injury 
post-operation. Significantly lower LDH (891.43±98.45 mU/mL, P<0.05) and AST (305.77±36.22 
IU/L, P<0.01) were observed in hiPSC-MSC-GPx3 group compared with control groups. Less 
apoptotic hepatocytes were observed and the remnant liver regeneration was more active in 
hiPSC-MSC-GPx3 group. In rat orthotopic liver transplantation model, more senescent 
hepatocytes were observed in small-for-size liver graft, in which GPx3 expression was significantly 
compromised. In mice IR injury model, hiPSC-MSC-GPx3 significantly suppressed hepatic 
senescence. In addition, rGPx3 inhibited cellular senescence of liver cells in a dose dependent 
manner. Four candidate genes (CD44, Nox4, IFNG, SERPERINB2) were identified to be 
responsible for suppressive effect of GPx3 on hepatic senescence.  
Conclusion: Engineered hiPSC-MSCs delivering GPx3 ameliorated hepatic IR injury via inhibition 
of hepatic senescence. 
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Introduction 
Orthotopic liver transplantation has been 
regarded as the best curative treatment for the 
patients with end stage of liver diseases including 
advanced liver cirrhosis and acute liver failure. 
Because of the severe shortage of grafts from 
brain-death donors and the importance of timely 
operation on recipients, living donor liver 
transplantation (LDLT) offers the unique opportunity 
of early transplantation with theoretically unlimited 
source of liver grafts. However, hepatic 
ischemia-reperfusion injury (IR injury) is still a severe 
problem worldwide, especially in the recipients with 
small-for-size liver graft [1, 2]. The destruction of 
hepatic sinusoidal endothelial architecture, which is 
resulted from transient hypertension in portal vein, 
contributes to prolonged ischemia period and severe 
inflammation after reperfusion [3]. This finding has 
also been validated in clinical series [4]. Therefore, 
development of novel therapeutic strategy targeting 
at small-for-size graft injury is an urgent need for liver 
transplantation [5]. Hepatic IR injury is mediated by 
overwhelming reactive oxygen species (ROS) 
released. Therefore, the application of anti-oxidant 
may be a potential therapeutic strategy. 
Glutathione peroxidase 3 (GPx3), an 
anti-oxidant, is always spontaneously expressed to 
protect the organ from oxidative stress by detoxifying 
hydrogen peroxide and other free radicals [6]. It has 
been reported that transcriptional expression of GPx3 
was significantly decreased after acute phase renal IR 
injury, which would cause persistent oxidative stress 
in renal tissues [7]. In addition to that, the plasma 
GPx3 was significantly lower in the patients with 
multiple organ failure and systemic inflammatory 
response [6]. Our previous study also showed that 
GPx3 is significantly down-regulated in small-for-size 
liver graft [8], in which the graft injury is much more 
severe [3]. It implies that the down-regulation of GPx3 
may contribute to severe organ damage.  
Oxidative stress induced hepatic senescence 
always triggers inflammatory response and further 
induces severe liver damage [9]. The infiltrating 
leukocytes are attracted to the injury site to remove 
the senescent hepatocytes for tissue repair. However, 
when the inflammatory response is overwhelming, 
the high level of (ROS) released from infiltrated 
leukocytes could cause over-consumption of GPx3 
[10] and further induce more senescent hepatocytes 
[11]. Then the vicious circle is established and liver 
damage is inevitable. It has been reported that cellular 
senescence could be accelerated in the 
micro-environment with down-regulation of GPx3 
[12]. Our preliminary study also showed that higher 
proportion of senescent hepatocytes was found in 
small-for-size liver graft, in which GPx3 expression 
was significantly compromised. Based on these 
findings, we hypothesize that application of GPx3 
may be a potential therapeutic strategy to reduce 
hepatic senescence and further ameliorate liver IR 
injury.  
The half-life time of GPx3 is relatively short and 
recombinant GPx3 (rGPx3) may not be cost-effective 
for further application. Therefore, a biocompatible 
delivery vehicle is required to carry and sustain GPx3 
for its anti-injury property. The mesenchymal stem 
cells (MSCs) are reported to be utilized as a delivery 
vehicle with the property of injury tropism. However, 
the aging related decreased function of bone marrow 
derived MSCs remains a severe problem [13]. Human 
induced pluripotent stem cells derived MSCs 
(hiPSC-MSCs) have been developed with higher 
proliferation rate and engraftment capacity [14]. 
Furthermore, hiPSC-MSC derived from patient 
specific iPSC is an optimal choice for liver diseases 
with larger production capacity and non-invasive 
harvesting nature. Based on these advantages, we 
established the engineered hiPSC-MSCs delivering 
GPx3 to conquer liver IR injury.  
In the current study, we aimed to explore the 
suppressive role of GPx3 delivered by hiPSC-MSCs in 
hepatic IR injury. Firstly, we established the 
engineered hiPSC-MSCs delivering GPx3 and 
examined whether GPx3 could be successfully 
delivered into the liver tissues. Then, we explored 
therapeutic value of hiPSC-MSC-GPx3 in mice IR 
injury model with partial hepatectomy. After that, we 
investigated the suppressive effect of GPx3 on injury 
induced hepatic senescence and further explore the 
possible mechanism. We hoped that our study could 
lay the foundation to develop novel therapeutic 
strategy targeting at hepatic IR injury.  
Material and Methods 
Establishment of engineered hiPSC-MSCs 
delivering GPx3 
The hiPSC-MSCs cell line was derived from our 
collaborator Dr. Lian [15]. The human iPSC cell lines 
(iMR90-5) were used for generation of MSCs. Then the 
iPSC cells were induced to differentiate to iPSC-MSCs 
using 10 ng/mL basic fibroblast growth factor (bFGF; 
GIBCO), 10 ng/mL platelet-derived growth factor AB 
(Peprotech, Rocky Hill, NH), and 10 ng/mL 
epidermal growth factor (Peprotech) for 1 week. The 
CD24-CD105+ cells were sorted by fluorescence- 
activated cell sorting (FACS) system. The surface 
markers of MSCs were further confirmed using 
flow-cytometry. The single cell clone was picked up 
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for further culture. After that, the full-length human 
GPx3 gene was transduced into expression plasmid 
pCDH-CMV-MCS-EF1-copGFP (System Biosciences, 
SBI). Virus particles were packaged in 293FT cells 
(System Biosciences, SBI). Expression of GPx3 after 
transduction was confirmed by western-blot and 
ELISA. Stem cells property was investigated after 
transduction using flow cytometry. The delivery 
vehicle (hiPSC-MSC-GPx3) was constructed as 
previously described [16].  
Mouse hepatic IR injury model with partial 
hepatectomy 
The mice IR injury model with partial 
hepatectomy was developed to mimic the liver 
transplantation with a small-for-size graft [17, 18]. In 
order to avoid the confounding factors of rat 
transplantation model, we use mice IR injury model 
with partial hepatectomy for functional studies in the 
present study. The mouse IR injury model with partial 
hepatectomy was established as previously described 
[18]. The rodent species for mice IR injury model is 
C57/B6. All the mice were subjected to partial 
hepatectomy (left and caudate lobes removed) and 
hepatic IR injury (right hepatic pedicle was clamped 
for 1 hour followed by different reperfusion period). 
hiPSC-MSC-GPx3 (5×104 cells/100µL PBS) was 
injected via portal vein after reperfusion. All the mice 
were segregated into three groups: control group (PBS 
injected), vector control group (hiPSC-MSC-pCDH 
injected) and GPx3 treatment group (hiPSC-MSC- 
GPx3 injected). 
Rat orthotopic liver transplantation model 
Male inbred Buffalo rats (body weight: 300-350g) 
were used as donors and recipients for 
transplantation. All the rats were kept with access to 
water and chow in a standard animal laboratory. They 
were housed with a 12-hour light/dark cycle and 
fasted 12 hours before transplantation. All operations 
were performed under clean conditions. The study 
had been licensed according to Animal (Control of 
Experiments) Ordinance Chapter 340 by the 
Department of Health, Hong Kong Special 
Administrative Region (ref.: (11–632) in DH/HA&P/ 
8/2/3 Pt. 31). A rat non-arterialized orthotopic liver 
transplantation model was established using whole 
graft and small-for-size graft as donors [19, 20]. The 
median graft ratio in small-for-size graft group (the 
ratio of graft weight to recipient liver weight) was 
55% (48-60%). We have already previously 
demonstrated that the survival rate of the rats with 
small-for-size liver graft is significantly shorter 
compared to those with whole liver grafts [1]. 
However, in our present study, all the rats were 
survived until sacrifice. The rats were sacrificed at 
days 1, 3, 5 after transplantation for collecting liver 
tissues and blood samples.  
Simulated IR injury model 
MIHA cells were purchased from the American 
Type Culture Collection (Manassas, VA, USA). MIHA 
is an immortalized non-tumorigenic normal human 
hepatocyte cell line. The simulated IR injury model 
was established as previously described [21]. The 
MIHA cells were cultured with mineral oil for 1 hour 
to mimic the ischemia period. The mineral oil was 
then replaced with normal culture Medium DMEM 
with 10%FBS for different time points to mimic the 
reperfusion period. 
Immunohistochemistry (IHC) staining 
Sections of paraffin-embedded tissue (4 μm) 
were stained as previously described [22]. 
Anti-human fibroblast antibody (CALBIOCHEM) and 
anti-human GPx3 antibody (Abnova) were used in the 
present study. 
H&E staining, TUNEL assay and Ki67 staining 
The liver histology change, hepatic apoptosis 
and liver regeneration were evaluated as previously 
described [17, 18].  
Detection of hepatic senescence 
In in vivo study, hepatic senescence was detected 
by IHC staining using p16/ink4a (Cell signaling) as 
marker. In in vitro study, hepatic senescence was 
detected using Senescence β-Galactosidase Staining 
Kit (9860s, Cell signaling). The detection was 
performed according to the manufacturer’s 
instruction. 1 ml of the β-Galactosidase Staining 
Solution was added into each 35 mm well. The plate 
was sealed with parafilm to prevent evaporation. The 
cells were then incubated at 37℃ for overnight in a 
dry incubator (no CO2). After that, the cells were 
checked under a microscope (200×) for the 
development of blue color. 
Senescent hepatocytes induced in vitro 
Senescent hepatocytes were induced according 
to the well-established protocol [23]. According to our 
preliminary study, we have revised the protocol in the 
present study (500µM H2O2 for 2 hours followed by 
normal medium culture for 48 hours).  
RT2 Profiler PCR array 
The senescence related signaling pathways were 
analyzed using RT² Profiler PCR Array according to 
instruction manual (PAHS-050ZC, Qiagen). The 
Human Cellular Senescence RT² Profiler PCR Array 
profiles the expression of 84 key genes involved in the 
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initiation and progression of the biological process 
causing cells to lose the ability to divide. This array 
includes genes involved in the primary senescence 
program and known stresses that cause premature 
senescence. The differentially expressed gene 
candidates, using 2-fold as cutoff point, were 
identified in senescent hepatocytes (MIHA cells 
treated by 500µM H2O2 for 2 hours) after rGPx3 
treatment (cultured with 2µg/dL rGPx3 for 48 hours).  
Detection of GPx3 expression 
The expression level of GPx3 was detected by 
qRT-PCR and Western-blot as previously described 
[16, 18, 24]. Rat plasma GPx3 was detected using 
Glutathione peroxidase assay kit (BioVsion). 
Statistical analysis  
The Chi-square test was used to compare 
categorical data. Paired or unpaired T test were 
adopted to compare continuous variables. P < 0.05 
was considered as statistically significant. Calculation 
was made using SPSS computer software version 16 
(SPSS Inc, Chicago, IL, USA). 
Results 
GPx3 could be successfully delivered by 
hiPSC-MSCs into liver tissues  
In order to explore the role of GPx3 in hepatic IR 
injury, mice IR injury model with partial hepatectomy 
was established. Engineered hiPSC-MSCs delivering 
GPx3 were injected via portal vein after reperfusion. 
According to IHC staining, we could see hiPSC-MSCs 
could be attracted into the injury site of liver tissues 
(Figure 1, upper panel). Most importantly, we found 
that GPx3 can be successfully detected in 
hiPSC-MSC-GPx3 treatment group, but not in 
hiPSC-MSC-pCDH (Vector control) group (Figure 1, 
middle panel). It implied that GPx3 could be 
successfully delivered by hiPSC-MSCs into liver 
tissues.  
hiPSC-MSC-GPx3 significantly ameliorated 
hepatic IR injury 
In order to examine the effect of 
hiPSC-MSC-GPx3 in mice IR injury model, tissue 
sectioning and serological tests were performed. H&E 
staining showed more hydropic degeneration and 
necrotic areas in the control and hiPSC-MSC-pCDH 
groups (Figure 2A, left and middle panel). In 
hiPSC-MSC-GPx3 treatment group, the structure of 
liver lobule was relatively intact (Figure 2A, right 
panel). Moreover, liver function was significantly 
improved by hiPSC-MSC-GPx3 treatment (Figure 2B). 
The LDH and AST level was dramatically dropped at 
day 1 and 3 in hiPSC-MSC-GPx3 treatment group. 
 
 
Figure 1. IHC staining showed that GPx3 could be successfully delivered by hiPSC-MSCs into the liver tissues, 400×. Arrows indicated the positive 
signals. 
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Figure. 2. Engineered hiPSC-MSCs delivering GPx3 significantly ameliorated hepatic IR injury and improved liver function. (A) H&E staining 
showed that more hydropic degeneration and necrotic areas in the control groups. The structure of liver lobes was more intact in the hiPSC-MSC-GPx3 treatment 
group, 400×. Dash lines indicated the necrotic area of liver tissues. Arrows indicated the ballooning change. (B) Serological test showed that liver function was 
improved upon hiPSC-MSC-GPx3 treatment, *P<0.05.  
 
hiPSC-MSC-GPx3 suppressed hepatic 
apoptosis and promoted liver regeneration 
In control and hiPSC-MSC-pCDH groups, more 
apoptotic hepatocytes were observed. In hiPSC- 
MSC-GPx3 group, hepatic apoptosis was significantly 
inhibited (Figure 3A and Figure S2A). Furthermore, 
liver regeneration was more active in hiPSC- 
MSC-GPx3 group at day 3 and day 5 post-operation 
(Figure 3B). Most importantly, the positive signal of 
liver regeneration could be detected as early as day 1 
post-operation upon GPx3 treatment. In contrast, liver 
regeneration could not be detected either in control or 
hiPSC-MSC-pCDH group at day 1 (Figure 3B). It 
implied that liver regeneration was more active and 
earlier upon GPx3 treatment.  
More senescent hepatocytes were found in 
small-for-size liver graft, in which expression of 
GPx3 was significantly compromised 
In order to longitudinally observe GPx3 
expression, the simulated IR injury model was 
established. We found that GPx3 could be 
spontaneously expressed in liver cells 24h and 48h 
after simulated IR injury (Figure 4A). However, this 
spontaneous expression of GPx3 was significantly 
compromised in small-for-size liver graft in 
orthotopic rat liver transplantation model (Figure 4B). 
Our previous studies also showed that liver injury 
was much more severe in the small-for-size graft [1-5, 
17, 18, 20, 21], in which GPx3 was significantly 
downregulated [8]. In order to further explore the 
potential mechanism of down-regulation of GPx3 
mediating liver graft injury, we further investigate the 
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change of hepatic senescence in orthotopic rat liver 
transplantation model. We found that higher 
proportion of senescent hepatocytes was observed in 
small-for-size liver graft (Figure 4C and Figure S2B), 
in which GPx3 expression was significantly 
compromised (Figure 4B). It implied that hepatic 
senescence could be accelerated in the micro- 
environment with lower production of GPx3.  
 
 
Figure 3. Engineered hiPSC-MSCs delivering GPx3 significantly suppressed hepatic apoptosis and promoted liver regeneration. (A) TUNEL 
staining showed that more apoptotic hepatocytes were observed in the control groups. (B) Ki67 staining showed that liver regeneration was more active upon 
hiPSC-MSC-GPx3 treatment, 400×. Arrows indicated the positive signals of liver regeneration. 
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Figure 4. More senescent hepatocytes were observed in small-for-size liver graft, in which the spontaneous expression of GPx3 was significantly 
compromised. (A) GPx3 could be spontaneously expressed in simulated IR injury model in vitro. Upper panel: expression of GPx3 protein. Lower panel: expression 
of GPx3 mRNA. (B) Spontaneous expression of GPx3 was significantly compromised in small-for-size liver graft in a rat orthotopic liver transplantation model, 
*P<0.05. (C) More senescent hepatocytes were observed in small-for-size liver graft in the rat orthotopic liver transplantation model. 
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GPx3 supplementation suppressed hepatic 
senescence in vitro and in vivo 
We found that lower production of GPx3 
accelerated hepatic senescence in rat liver 
transplantation model, then we further explore 
whether GPx3 supplementation could suppress 
hepatic senescence. In mice IR injury model, we 
observed that hepatic senescence was significantly 
attenuated by hiPSC-MSC-GPx3 treatment (Figure 5A 
and Figure S2C). In order to avoid the confounding 
factors in animal model, we further confirm the 
suppressive effect of GPx3 on hepatic senescence in 
vitro. The cellular senescence of liver cells was 
induced using 500µM H2O2 treatment for 1 hour and 
then the liver cells were cultured with normal 
medium. Forty eight hours later, we found that 
recombinant GPx3 protein (rGPx3) significantly 
suppressed hepatic senescence in LO2 and MIHA cells 
in a dose dependent manner (Figure 5B).  
 
 
Figure 5. GPx3 significantly suppressed hepatic senescence in vitro and in vivo. (A) GPx3 delivered by hiPSC-MSCs significantly suppressed hepatic 
senescence in the mice IR injury model. Arrows indicated the positive signals of senescent hepatocytes. (B) rGPx3 significantly suppressed hepatic senescence of 
MIHA and LO2 cells in a dose dependent manner in vitro. Arrows indicated the positive signals of senescent hepatocytes. 
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Table 1. Four gene candidates were identified to be responsible 
for suppressive effect of GPx3 on hepatic senescence. 
Symbol GenBank UniGene Description 
Down-regulated    
CD44 NM_000610 Hs.502328 CD44 molecule (Indian blood 
group) 
NOX4 NM_016931 Hs.371036 NADPH oxidase 4 
IFNG NM_000619 Hs.856 Interferon, gamma 
SERPINB2 NM_002575 Hs.594481 Serpin peptidase inhibitor, 
clade B (ovalbumin), member 2 
The Human Cellular Senescence RT² Profiler PCR Array profiles the expression of 
84 key genes involved in the initiation and progression of the biological process 
causing cells to lose the ability to divide. This array includes genes involved in the 
primary senescence program and known stresses that cause premature senescence. 
 
Four gene candidates were identified to be 
responsible for suppressive effect of GPx3 on 
hepatic senescence 
In order to further explore the underlying 
mechanism mediating the suppressive effect of GPx3 
on hepatic senescence, Human Cellular Senescence 
RT² Profiler PCR Array was performed to identify the 
potentially related signaling pathways. The cellular 
senescence of MIHA cells was induced in vitro. 48h 
after rGPx3 treatment, 4 down-regulated gene 
candidates (CD44, Nox4, IFNG, SERPINB2) were 
identified (Table 1). Three of them (CD44, Nox4, 
SERPINB2) were significantly up-regulated when 
cellular senescence was established (after H2O2 
treatment), and sharply decreased upon rGPx3 
treatment (Figure S1). It implied that these three genes 
may be related to initiation of oxidative stress induced 
cellular senescence and rGPx3 may suppress hepatic 
senescence via these signaling pathways. Expression 
of IFNG was not found to be up-regulated when 
senescence was established (Figure S1). However, 
IFNG was also sharply decreased upon rGPx3 
treatment. It implied that GPx3 may suppress the 
inflammatory response via inhibition of IFNG and 
further ameliorate liver IR injury.  
Discussion 
In the present study, we demonstrated that 
engineered hiPSC-MSCs delivering GPx3 significantly 
reduced hepatic senescence and further ameliorated 
liver IR injury. We previously reported that GPx3 
significantly suppressed tumor invasiveness and 
possesses therapeutic value for HCC patients after 
liver transplantation [8]. Based on our present and 
previous studies, application of GPx3 may be a “one 
stone for two birds” therapeutic strategy not only to 
prevent tumor recurrence, but also to ameliorate liver 
IR injury for HCC patients after liver transplantation.  
GPx3 is an anti-oxidant, which could protect the 
organ from overwhelming oxidative stress [6]. In the 
present study, we found that GPx3 could be 
spontaneously expressed in the simulated IR injury 
model. However, this spontaneous expression was 
significantly compromised in small-for-size liver graft 
in a rat liver transplantation model. This observation 
has also been validated in the clinical series [16]. It 
implied that the detoxification activity was 
significantly compromised in the small-for-size liver 
graft, in which the graft injury is much more severe 
[3]. There might be two explanations for lower 
production of GPx3 in small-for-size liver graft. On 
one hand, the production of GPx3 may be inhibited 
due to epigenetic alteration [25]. On the other hand, 
GPx3 may be over-consumed in the 
micro-environment with overwhelming ROS released 
[10]. It has also been reported that down-regulation of 
GPx3 exacerbates renal IR injury and promote fibrotic 
activity [7]. Our previous study also showed that 
more severe graft injury was observed in the 
small-for-size liver graft [3], in which GPx3 is 
significantly down-regulated [8]. Therefore, educating 
dysregulated micro-environment and recovering 
GPx3 supplementation might be a prospective 
strategy to conquer liver IR injury. However, the 
information about the role of GPx3 in liver IR injury is 
rather limited. Only one study showed that 
up-regulation of GPx3 protects against alcohol 
induced hepatic injury in mice [26]. In the present 
study, we demonstrated, for the first time, GPx3 
delivered by hiPSC-MSCs significantly ameliorated 
hepatic IR injury, suppressed hepatic apoptosis and 
promoted liver regeneration. Our finding was also 
supported by the reports that the treatments with 
compounds/drugs enhancing activity of hepatic 
GPx3 attenuate hepatic IR injury [27, 28]. It implied 
that the protective effect of GPx3 could be associated 
to the reduction of ROS formation. This finding may 
provide the new insights to educate the dysregulated 
micro-environment targeting at hepatic IR injury, 
especially for the patients with small-for-size liver 
graft. 
Oxidative stress induced hepatic senescence is 
one of the major reasons for severe liver IR injury [29]. 
The senescent hepatocytes show specific senescence 
associated secretion phenotypes (SASP) and induce 
enhanced inflammatory response [30], which would 
further aggravate liver IR injury [14]. Therefore, 
suppressing hepatic senescence is a prospective 
therapeutic strategy to conquer liver IR injury. It has 
been reported that attempting to elongate telomeres, 
such as inducing telomerase activity to promote liver 
regeneration, is one of the potential therapeutic 
options for attenuating hepatic senescence [31]. 
However, substantial risk of cellular transformation 
and carcinogenesis is a major concern. Expression of 
telomerase would enhance the opportunity of 
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bypassing the cell-cycle checkpoints and permitting 
unchecked replication of hepatocytes [31]. Our 
previous and present studies showed that the 
anti-oxidant, GPx3, not only suppressed hepatic 
senescence, but also inhibited tumor progression. 
Therefore, application of GPx3 may be a prospective 
strategy to reduce hepatic senescence without 
increasing the risk of carcinogenesis.  
As the half-life time of circulating GPx3 is 
relatively short, being only 10 hours [32, 33], and 
application of rGPx3 may not be cost-effective for 
further application. A novel biocompatible delivery 
system, which could carry and sustain GPx3 for its 
anti-injury property, is an urgent need. Lenti-virus is 
an efficient vector. However, safety issue is still a 
major concern due to insertional mutation and 
production of replication competent virus particles 
[34-36]. Engineered MSCs delivering 
anti-inflammatory agent was reported as a novel 
strategy with the advantage of injury tropism and 
fewer systemic side effects [37, 38]. Compared with 
bone marrow derived MSCs (BM-MSCs), 
hiPSC-MSCs showed higher proliferation rate and 
enhanced engraftment capacity [15]. In contrast with 
BM-MSCs, large amount of hiPSC-MSCs could be 
achieved and expanded from patient specific iPSCs 
with no obvious aging related deterioration effect 
[15]. Based on these findings, hiPSC-MSCs could be 
prepared as “off-the-shelf” resources derived from 
patients’ specific iPSCs for clinical application in the 
future. It has been reported that MSCs themselves 
could attenuate IR injury due to their 
immuno-modulated property [39, 40]. However, our 
study showed that no significant effect was observed 
by hiPSC-MSCs-pCDH treatment alone. The 
discrepancy may be attributed to the different amount 
of MSCs used for the therapy. It has been reported 
that the number of MSCs (4.5×106) for prevention of 
lung IR injury is quite high [41]. However, in our 
present study, engineered hiPSC-MSCs delivering 
GPx3 showed the advantage that only a small amount 
of hiPSC-MSCs (5×104) was needed to deliver GPx3 
and proven to be adequate to exhibit a significant 
therapeutic effect.  
In the present study, we found that GPx3 can be 
successfully delivered by hiPSC-MSCs into the liver 
tissues in the mice IR injury model. Then, we 
demonstrated that the engineered hiPSC-MSCs 
delivering GPx3 significantly ameliorated liver IR 
injury, suppressed hepatic apoptosis and promoted 
liver regeneration. After that, we found that more 
senescent hepatocytes were observed in the 
small-for-size liver graft, in which the expression of 
GPx3 is significantly compromised. Finally, we 
demonstrated that GPx3 supplementation 
significantly suppressed hepatic senescence in vitro 
and vivo. Based on these findings, we concluded that 
engineered hiPSC-MSCs delivering GPx3 significantly 
suppressed hepatic senescence and further 
ameliorated liver IR injury. We hoped that our study 
could provide the evidences to explore novel 
therapeutic strategy targeting at liver IR injury. The 
senescence related signaling pathways mediating the 
suppressive effect of GPx3 is worthwhile for the 
further investigation.  
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